Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of EyePoint Pharmaceuticals in a report released on Thursday, March 6th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.63) per share for the quarter, down from their prior forecast of ($0.44). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.81) EPS.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million for the quarter, compared to the consensus estimate of $11.02 million.

EYPT has been the topic of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday. Robert W. Baird cut their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. Finally, Citigroup began coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target for the company. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Stock Up 4.5 %

EyePoint Pharmaceuticals stock opened at $7.13 on Monday. EyePoint Pharmaceuticals has a 52-week low of $5.54 and a 52-week high of $26.06. The firm has a market capitalization of $486.63 million, a price-to-earnings ratio of -3.57 and a beta of 1.41. The firm has a 50-day moving average price of $7.25 and a two-hundred day moving average price of $8.45.

Institutional Trading of EyePoint Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP grew its holdings in EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after acquiring an additional 18,616 shares during the period. Intech Investment Management LLC bought a new position in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at about $136,000. Charles Schwab Investment Management Inc. grew its stake in shares of EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Patient Square Capital LP bought a new stake in shares of EyePoint Pharmaceuticals in the 3rd quarter worth approximately $10,882,000. Finally, Wellington Management Group LLP lifted its stake in EyePoint Pharmaceuticals by 59.4% during the third quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after purchasing an additional 64,008 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.